“Difficulties in employee retention.” “No assurance that we will be able to successfully raise sufficient additional capital.” “We may be forced to delay, reduce or eliminate some or all of our ...

Regeneron Pharmaceuticals has agreed to acquire Checkmate Pharmaceuticals for approximately $250 million cash, the companies said, in a deal that expands the buyer’s immuno-oncology pipeline with ...